In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low ...

How many, if any, cases of nervous system disorders have been reported because of A-C breast cancer chemotherapy? I'm 45 and had treatment at 39 and 40. I now experience a very exaggerated amount of ...

Repronovo announces first participant included in US phase 2 trial of RPN-001 to treat MALE INFERTILITY: Lausanne, Switzerland Wednesday, July 2, 2025, 14:00 Hrs [IST] ReproNovo, ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

The study compared camizestrant in combination with CDK4/6 inhibitor drugs – such as Pfizer's Ibrance (palbociclib), Novartis' Kisqali (ribociclib), or Eli Lilly's Verzenios (abemaciclib) – to ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Hypertension affects 1 in 3 adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone ...

Panelists emphasize that effective use of menin inhibitors for KMT2A-rearranged acute myeloid leukemia (AML) requires dispelling common misconceptions about oral targeted therapy, ensuring close ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

Researchers at the School of Chinese Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), have found that ...